Strengthening the company’s capacity to detect infectious agents, “Central Laboratory” has invested 1 million euros in the purchase of the world’s most modern molecular biological testing equipment, informs the company’s representative Līga Ribkinska.
–
–
Content will continue after the ad
Advertising
–
“Central Laboratory” as the leading Covid-19 diagnostician in Latvia, in addition to existing technologies, has acquired a world-renowned, widely used and the only Chemagic 360-D (Perkin Elmer) device in the Baltics, which is suitable not only for Covid-19 examinations, but also for tick-borne diseases. . The Cobas 6800 System (Roche Diagnostics), on the other hand, allows a larger sample flow to be processed on a daily basis and maintains the quality of Covid-19 testing. Technologies of this class are starting to be used in Latvia directly under the influence of a pandemic. For their use to be cost-effective, there is a sufficient demand for molecular tests and they are commonly used in large populations.
“It is a fully automated molecular biology device – a system that determines the genetic material of pathogens. There are very few such devices in our region because they are designed for a large flow of samples and are relatively expensive. This system can work around the clock and is available 24 hours a day. “We are currently testing Covid-19 with the new equipment, but in the future this technology could be used to detect influenza, HIV, hepatitis and other infectious agents,” said Yelena Storozhenko, a member of the board of the Central Laboratory.
Due to the pandemic, the need for diagnostic services has significantly increased, and the demand is active both on weekends and holidays, in work teams and in various other hitherto inexperienced situations.
“The functionality of these technologies already significantly facilitates the management of daily work processes and allows to improve the efficiency of the company, which is vital in our case, considering that on weekdays we perform about 30% and on weekends about 48% of all Covid-19 analyzes in Latvia.” reveals Storozhenko.
“When evaluating investment objects, we pay a lot of attention to automation, because it eliminates the need for manual work in managing complex processes, thus minimizing the impact of the human factor on testing. The winners are everyone – customers receive test results faster, but employees reduce manual workload. is engaged in the operation and maintenance of this equipment, must be at a high professional level, so we work with partners from Switzerland, Germany, Great Britain and other European countries, training and supplementing the qualifications of our laboratory specialists, “says Storozhenko.
“Central Laboratory” has been working in the field since 1994. Currently, the sample logistics covers the entire territory of Latvia, there is a mobile sampling team at home, a call center and 36 Covid-19 analysis transfer points, which are also located throughout Latvia, while the number of branches reaches 65. The company offers the widest range of laboratory analysis services, specialist consultations and Approximately 6.5 million analyzes are performed during the year.
“Repharm” is a group of Latvian companies working in the field of healthcare, which unites “Sentor Farm aptiekas” (brand “Mēness aptieka”), JSC “Veselības centru liittība”, SIA “Centrālā laboratorija”, “Rīgas farmaceitiskā fabrika” and “Recipe Plus” .
Repharm Group of Companies was established in 2009. In 2019, the turnover of the Repharm Group was 283.008 million euros, but the profit of the group was 34.56 million euros.
According to Firmas.lv, the real beneficiaries of Repharm are several Latvian individuals – Roberts Tavjevs, Jānis Oskerko, Mihails Lurje, Aleksandrs Livšics, Andrejs Leibovičs, Sergejs Korņijenko, Josifs Apts and Jelena Nikitina.
–
